Charcot's foot: Newest findings on its pathophysiology, diagnosis and treatment;Le pied de Charcot: actualités physiopathologiques, diagnostiques et thérapeutiques

Diabetes and Metabolism

Volumn 36, Issue 4, 2010, Pages 251-255

  Molines, L ^a   Darmon, P ^a   Raccah, D ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Charcot neuro osteoarthropathy; Diabetic foot; Diabetic neuropathy; Osteoprotegerin; RANK L; Review

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SALCATONIN; TECHNETIUM 99M;

BONE SCINTISCANNING; BONE TURNOVER; CHARCOAT NEUROOSTEOARTHROPATHY; CHARCOT NEUROOSTEOARTHROPATHY; CLINICAL TRIAL; DIABETIC FOOT; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; FOOT; FOOT CARE; HUMAN; IMMOBILIZATION; INCIDENCE; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHROPATHY; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PREVALENCE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT OUTCOME; WALKING AID; X RAY;

ALENDRONATE; ARTHROPATHY, NEUROGENIC; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIABETIC FOOT; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; EARLY DIAGNOSIS; FOOT DEFORMITIES, ACQUIRED; FOOT INJURIES; HUMANS; OSTEOPROTEGERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; WEIGHT-BEARING;

EID: 77956958225     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.04.002     Document Type: Review

References (43)

1. Mitchell J.K. On a new practice in acute and chronic rheumatism. Am J Med Sci 1831, 8:55-64.
2. Mitchell J.K. Further cases and observations relative to rheumatism. Am J Med Sci 1833, 12:360.
3. Charcot J.M. Sur quelques arthropathies qui paraissent dépendre d'une lésion du cerveau ou de la moelle épinière. Arch Physiol Norm Pathol 1868, 1:161-178.
4. MacCormac W, Klockmann JW. Transactions of the international medical congress: seventh session held in London, August 2-9 1881 vol.1. Ballantyne, Hanson & Co: London 1881; p. 128-29.
5. Jordan W.R. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936, 57:307-366.
6. Nagarkatti D.G., Banta J.V., Thomson J.D. Charcot arthropathy in spina bifida. J Pediatr Orthop 2000, 20:82-87.
7. McKay D.J., Sheehan P., DeLauro T.M., Iannuzzi L.M. Vincristine-induced neuroarhtropathy (Charcot's joint). J Am Podiatr Med Assoc 2000, 90:478-480.
8. Horibe S., Tada K., Nagano J. Neuroarthropathy of the foot in leprosy. J Bone Joint Surg Br 1988, 70:481-485.
9. Vera A.I., Nixon B.P. Charcot foot in an alcoholic patient. A case report. J Am Podiatr Med Assoc 1995, 85:318-320.
10. Rajbhandari S.M., Jenkins R.C., Davies C., Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002, 45:1085-1096.
11. Edmonds M.E., Petrove N.L., Elias D.A. The earliest magnetic resonance imaging sign of mid-foot charcot osteoarthropathy is oedema of subchondral (subarticular) bone marrow which needs prompt therapeutic offloading. Diabet Med 2005, 22(Suppl. 2):93. P272.
12. Chantelau E., Poll L.W. Evaluation of the diabetic foot by MR imaging or plain radiography-an observational study. Exp Clin Endocrinol Diabetes 2006, 114:428-431.
13. Schlossbauer T., Mioc T., Sommerey S., Kessler S.B., Reiser M.F., Pfeifer K.J. Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. Eur J Med Res 2008, 22:409-414.
14. Sanders L.J., Frykberg R.G. Diabetic neuropathic osteoarthropathy: the Charcot foot. The high risk foot in diabetes mellitus. 1991, 297-333. Churchill Livingstone, New York. R.G. Frykberg (Ed.).
15. Edmonds M.E., Clarks M.B., Newton S., Barrett J., Watkins P.J. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 1985, 57:843-855.
16. Jeffcoate W.J., Game F.L., Cavanagh P.R. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005, 366:2058-2061.
17. Baumhauer J.F., O'Keefe R.J., Schon L.C., Pinzur M.S. Cytokine-induced osteoclastic bone resorption in Charcot arthropathy: an immunohistochemical study. Foot Ankle Int 2006, 27:797-800.
18. Petrova N.L., Moniz C., Elias D.A., Buxton-Thomas M., Bates M., Edmonds M.E. Is there a systemic inflammatory response in the acute Charcot foot?. Diabetes Care 2007, 30:997-998.
19. Jeffcoate W.J. Vascular calcification and osteolysis in diabetic neuropathy Is RANK-L the missing link?. Diabetologia 2004, 47:1488-1492.
20. Vega D., Maalouf N.M., Sakhaee K. The role of receptor activator of nuclear factor-κB (RANK)/RANK Ligand/Osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92:4514-4521.
21. Jeffcoate W.J. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 2008, 24(Suppl. 1):S62-S65.
22. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differenciation and activation. Nature 2003, 423:337-342.
23. Jeffcoate W.J., Rasmussen L.M., Hofbauer L.C., Game F.L. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia 2009, 52:2478-2488.
24. Sinha S., Munichoodappa C., Kozak G.P. Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972, 51:191-210.
25. Clouse M.E., Gramm H.F., Legg M., Flood T. Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. Am J Roentgenol Radium Ther Nucl Med 1974, 121:22-33.
26. Mabilleau G., Petrova N.L., Edmonds M.E., Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008, 51:1035-1040.
27. Pitocco D., Zelano G., Gioffrè G., Di Stasio E., Zaccardi F., Martini F., et al. Diabetes Care 2009, 32:1694-1697.
28. Frykberg R.G., Mendeszoon E. Management of the diabetic Charcot foot. Diabetes Metab Res Rev 2000, 16(Suppl. 1):S59-S65.
29. Pinzur M.S., Shields N., Trepman E., Dawson P., Evans A. Current practice patterns in the treatment of Charcot foot. Foot Ankle Int 2000, 21:916-920.
30. McGill M., Molyneaux L., Bolton T., Ioannou K., Uren R., Yue D.K. Response of Charcot's arthropathy to contact casting: assessment by quantitative techniques. Diabetologia 2000, 43:481-484.
31. Armstrong D.G., Todd W.F., Lavery L.A., Harkless L.B., Bushman T.R. The natural history of acute Charcot's arthropathy in a diabetic foot speciality clinic. Diabet Med 1997, 14:357-363.
32. Sinacore D.R. arthropathy inpatients with diabetes mellitus: healing times by foot location. J Diabetes Complicat 1998, 12:287-293.
33. Lavery L.A., Armstrong D.G., Walker S.C. Healing rates of diabetic foot ulcers associated with midfoot fracture due to Charcot's arthropathy. Diabet Med 1996, 14:46-49.
34. Mehta J.A., Brown C., Sargeant N. Charcot restraint orthotic walker. Foot Ankle Int 1998, 19:619-623.
35. Guse S.T., Alvin F.G. Treatment of diabetic foot ulcers and Charcot neuroarthropathy using the patellar tendon-bearing brace. Foot Ankle Int 1997, 18:675-677.
36. Yalsin S., Kocaoglu B., Berker N., Erol B. Conservative treatment of Charcot artroparthy in a series of spina bifida patients: the experience of one center and review of the literature. J Pediatr Othop B 2007, 16:376-379.
37. Boninger M.L., Leonard J.A. Use of bivalved ankle-foot orthosis in neuropathic foot and ankle lesions. J Rehabil Res Dev 1996, 33:16-22.
38. Hartsell H.D., Fellner C., Saltzman C.L. Pneumatic bracing and total contact casting have equivocal effects on plantar pressure relief. Foot Ankle Int 2001, 22:502-506.
39. Jude E.B., Selly P.L., Burgess J., Lilleystone P., Mawer E.B., Page S.R., et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double blind randomised controlled trial. Diabetologia 2001, 44:2032-2037.
40. Pitocco D., Ruotolo V., Caputo S., Mancini L., Collina C.M., Manto A., et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005, 28:1214-1215.
41. Bem R., Jirkovska A., Fejfarova V., Skibova J., Jude E.B. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 2006, 29:1392-1394.
42. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
43. Cohen S.B., Dore R.K., Lane N.E., Ory P.A., Peterfy C.G., Sharp J.T., et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in Rheumatoid Arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309.